
Gentian Diagnostics ASA
GENT | OL
Overview
Corporate Details
- ISIN(s):
- NO0010748866
- LEI:
- 5967007LIEEXZXHNM861
- Country:
- Norway
- Address:
- Bjørnåsveien 5, 1596 Moss
- Website:
- https://www.gentian.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Gentian is a Norwegian IVD company that specialises in developing and manufacturing turbidimetric assays that enable clinical lab professionals to achieve greater operational efficiency, thus providing faster patient results to clinicians. The current portfolio and pipeline of diagnostic reagents span areas of kidney disease, cardiac disease, inflammation, infection and veterinary medicine. By leveraging both our expertise in Particle-Enhanced Turbidimetric Immunoassays (PETIA) and proprietary nanoparticle technology, we develop immunoassays that enable users to transition from traditional low volume immunology platforms to fully automated clinical chemistry instruments. The typical Gentian customer enjoys shorter turnaround times, streamlined workflows and improved cost efficiency.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-06-02 16:34 |
Major Shareholding Notification
Flaggemelding Gentian Diagnostics ASA
|
Norwegian | 495 bytes | |
2025-05-23 09:39 |
Major Shareholding Notification
Disclosure of shareholding
|
English | 986 bytes | |
2025-05-22 08:47 |
Directors' Dealings
Disclosure of large shareholding
|
English | 893 bytes | |
2025-05-08 08:00 |
Directors' Dealings
Mandatory notification of trade
|
Norwegian | 131.6 KB | |
2025-05-08 08:00 |
Directors' Dealings
Mandatory notification of trade
|
English | 1.4 KB | |
2025-05-07 06:07 |
Regulatory News Service
Gentian Diagnostics: Ex dividend NOK 0.40 today
|
Norwegian | 708 bytes | |
2025-05-07 06:00 |
Regulatory News Service
Gentian Diagnostics: First quarter 2025 report
|
English | 2.1 MB | |
2025-05-07 06:00 |
Earnings Release
Gentian Diagnostics: First quarter 2025 report
|
English | 750.7 KB | |
2025-05-07 06:00 |
Earnings Release
Gentian Diagnostics: First quarter 2025 report
|
English | 2.7 KB | |
2025-05-06 10:14 |
Regulatory News Service
Gentian Diagnostics: Minutes from Annual General Meeting
|
English | 7.0 MB | |
2025-05-06 10:14 |
Regulatory News Service
Gentian Diagnostics: Minutes from Annual General Meeting
|
English | 724 bytes | |
2025-04-30 08:10 |
Regulatory News Service
Gentian Diagnostics: Invitation to presentation of first quarter results
|
English | 726 bytes | |
2025-04-11 10:56 |
Regulatory News Service
Gentian Diagnostics: Notice of annual general meeting
|
English | 1.5 MB | |
2025-04-11 10:56 |
Regulatory News Service
Gentian Diagnostics: Notice of annual general meeting
|
English | 776 bytes | |
2025-04-07 12:23 |
Directors' Dealings
Mandatory notification of trade
|
English | 123.1 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
BIG Technologies PLC | United Kingdom | BIG | |
|
BioArctic | Sweden | BIOA | |
![]() |
Bioceltix S.A. | Poland | BCX | |
![]() |
Bioextrax AB | Sweden | BIOEX | |
|
Biofrontera AG | Germany | B8F | |
![]() |
BioGaia | Sweden | BIOG | |
![]() |
Biohit Oyj | Finland | BIOBV | |
![]() |
BioInvent International | Sweden | BINV | |
![]() |
BioLineRx Ltd. | Israel | BLRX | |
![]() |
Biophytis S.A. | France | ALBPS |